CoChat

Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. In preclinical studies, SP1049C demonstrated increased efficacy compared to doxorubicin. The objectives of this first phase I study were to determine the toxicity profile, dose-limiting toxicity, maximum tolerated dose and pharmacokinetic profile of SP1049C, and to document any antitumour activity. The starting dose was 5 mg m(-2) (doxorubicin content) as an intravenous infusion once every 3 weeks for up to six cycles. A total of 26 patients received 78 courses at seven dose levels. The dose-limiting toxicity was myelosuppression and DLT was reached at 90 mg m(-2). The maximum tolerated dose was 70 mg m(-2) and is recommended for future trials. The pharmacokinetic profile of SP1049C showed a slower clearance than has been reported for conventional doxorubicin. Evidence of antitumour activity was seen in some patients with advanced resistant solid tumours. Phase II trials with this agent are now warranted to further define its antitumour activity and safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6601856

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structures of (A) doxorubicin (B) block copolymers.
Figure 1 Structures of (A) doxorubicin (B) block copolymers.CC BY · PubMed Central
Figure 2 AUC vs dose level.
Figure 2 AUC vs dose level.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. Lohri A, Gelmon KA, Embree L, Mayer L, Cullis P, Saletan S, Goldie J (1991) Phase I/II study of liposome encapsulated doxorubicin (TLC-D-99) in non small cell lung cancer. Proc Am Soc Clin Oncol 10: A292

Cited by

See all 386

Metadata

Authors
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M.
Affiliations
  • The Christie Hospital (GB)
  • Queen Elizabeth Hospital Birmingham (GB)
  • Supratek Pharma (Canada) (CA)
  • Cancer Research UK (GB)
  • University of Strathclyde (GB)
Corresponding author
Ranson, M
Venue
British Journal of Cancer
Published
2004-05-04
Volume
90
Issue
11
Pages
2085-2091
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2159334966
Cited by
382
References
20
Citations by year
2026: 6 · 2025: 7 · 2024: 8 · 2023: 8 · 2022: 17 · 2021: 7 · 2020: 18 · 2019: 13 · 2018: 11 · 2017: 22 · 2016: 26 · 2015: 26 · 2014: 26 · 2013: 32 · 2012: 26
FWCI
5.82
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Keywords
doxorubicin, Pluronic block copolymers, advanced cancer, dose-limiting toxicity, myelosuppression, maximum tolerated dose, pharmacokinetics, antitumour activity, drug resistance, solid tumors
MeSH terms
Adult, Aged, Antibiotics, Antineoplastic, Doxorubicin, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neoplasms, Polymers, Poloxamer, Maximum Tolerated Dose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6601856
The paper
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004). Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6601856

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.